Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Baselga

Showing results (101-110 of 168) with videos related to

Pageof 17
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2018
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabS M Swain, A Schneeweiss, L Gianni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 7, 2017
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabS M Swain, A Schneeweiss, L Gianni, et al.
The New England Journal of Medicine|March 15, 2001
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2D J Slamon, B Leyland-Jones, S Shak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabS M Swain, A Schneeweiss, L Gianni, et al.
Oncogene|December 9, 2008
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicityM Scaltriti, C Verma, M Guzman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2007
Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancerA Prat, M Parera, S Peralta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2008
Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levelsA Prat, M Parera, B Adamo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancerA D Seidman, C A Hudis, J Albanell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline responseA D Seidman, B S Reichman, J P Crown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumorsJ Balmaña, N M Tung, S J Isakoff, et al.
Pageof 17

Showing results (101-110 of 168) with videos related to

Sort By:
Pageof 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2018
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabS M Swain, A Schneeweiss, L Gianni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 7, 2017
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabS M Swain, A Schneeweiss, L Gianni, et al.
The New England Journal of Medicine|March 15, 2001
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2D J Slamon, B Leyland-Jones, S Shak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabS M Swain, A Schneeweiss, L Gianni, et al.
Oncogene|December 9, 2008
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicityM Scaltriti, C Verma, M Guzman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2007
Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancerA Prat, M Parera, S Peralta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2008
Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levelsA Prat, M Parera, B Adamo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancerA D Seidman, C A Hudis, J Albanell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline responseA D Seidman, B S Reichman, J P Crown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumorsJ Balmaña, N M Tung, S J Isakoff, et al.
Pageof 17